Latigo Biotherapeutics, Inc.

Latigo Biotherapeutics, Inc. が 2026年9月3日 に発表した内容

企業自身の 8-K から。

決算説明会

Latigo Biotherapeutics, Inc. の決算説明会の書き起こしはありません。

経営陣の発言

“This has been a significant period for Latigo as we completed our upsized initial public offering, published positive onzotrigine abdominoplasty results in moderate-to-severe acute pain in The New England Journal of Medicine, and continued to advance our pipeline of innovative pain programs,”

発表資料から逐語で引用し、書類が氏名のある人物に帰属させている場合にのみ表示します。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Latigo Biotherapeutics, Inc. の事業内容

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines. Latigo’s drug candidates are designed to rapidly and effectively stop the transmission of pain without the risk of addiction. The Company’s lead product candidate, onzotrigine (previously referred to as LTG-001) is an oral Na v 1.8 ion channel inhibitor intended to provide fast-acting, opioid-sparing relief for the treatment of acute pain. LTG-321 is an oral Na v 1.8 inhibitor being developed for chronic musculoskeletal pain. Additionally, Latigo is advancing research of additional Na v 1.8 inhibitors that can address alternative formulation and delivery approaches as well as other ion channel targets for the treatment of pain. Learn more at latigobio.com or follow us on LinkedIn and X .

発表資料の末尾に記載された、企業自身による説明です。